<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01105403</url>
  </required_header>
  <id_info>
    <org_study_id>POL-2</org_study_id>
    <nct_id>NCT01105403</nct_id>
  </id_info>
  <brief_title>Exploratory Study on POL6326 in Stem Cell Mobilization</brief_title>
  <official_title>A Phase IIa, Proof of Concept Study is to Determine the Degree of Mobilisation of CD34+ Cells Following Administration of POL6326 in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polyphor Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polyphor Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether POL6326 is safe and clinically active to
      mobilize hematopoietic stem cells followed by transplantation
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the ability of POL6326 to mobilise CD34+ hematopoietic stem cells in patients with primary multiple myeloma</measure>
    <time_frame>Up to four days</time_frame>
    <description>Number of patients achieving the minimal number of CD34+ cells (≥2 x 10 mill/kg BW) collected during one to four cycles of apheresis which are considered necessary and safe to proceed with autotransplantation
Number of apheresis cycles required to obtain the minimal number of CD34+ cells necessary for autotransplantation (≥2 x 10 mill/kg BW)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and pharmacokinetics of POL6326 in patients with multiple myeloma</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the efficacy of POL6326 in reconstitution of immune system after transplantation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CD34+ mobilisation for transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>POL6326</intervention_name>
    <description>IV infusion of POL6326 followed by apheresis to collect mobilized stem cells from peripheral blood</description>
    <arm_group_label>CD34+ mobilisation for transplantation</arm_group_label>
    <other_name>not appicable</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have multiple myeloma in Stage II or III, according to the criteria of Durie and
             Salmon.

          2. Male or female between 18 and 70 years of age, inclusive. Male and females capable of
             reproduction must agree to use adequate contraceptive measures (e.g. condom,
             intrauterine device, oral contraceptive) until 3 months after termination of
             treatment.

          3. Measurable disease, defined by one of the following:

               -  Serum M protein ≥1.0 g/dL by protein electrophoresis

               -  Quantifiable immunoglobulin levels and/or

               -  urinary M protein excretion ≥200 mg/24 hours.

          4. All patients have undergone 3 cycles of chemotherapy, with the last dose of
             chemotherapy given 3 to 8 weeks before study entry.

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 2.

          6. Life expectancy of &gt;6 months.

          7. Have given their written informed consent to participate in the study

        Exclusion Criteria:

          1. Have non-secretory myeloma and/or plasma cell leukaemia.

          2. History of other malignancies during the past 5 years, with the exception of
             adequately treated basal or squamous cell carcinoma of the skin, cervical carcinoma,
             or localised prostate carcinoma.

          3. Any other clinically significant medical conditions.

          4. History of cardiac disease NHYA classification ≥3.

          5. Insufficient bone marrow, liver and renal function as assessed by the following
             clinical laboratory evaluations:

             Haemoglobin &lt;9.0 g/L. Absolute neutrophil count &lt;1500/µL. Platelet count &lt;50000/µL.
             Total bilirubin &gt;1.5 x upper limit of normal (ULN). Alanine aminotransferase (ALT) and
             alkaline phosphatase (AP) &gt;2.5 x ULN. Amylase and lipase &gt;1.5 x ULN. Serum creatinine
             &gt;2.0 x ULN. Prothrombin time (PT) and activated partial thrombo-plastin time (aPTT)
             &gt;1.5 x ULN.

          6. Pregnant or lactating female patients.

          7. Known history of HIV infection or chronic hepatitis B or C infection.

          8. Receipt of immunotherapy, radiation therapy, or any investigational drug within 30
             days of study drug administration.

          9. Prior radiotherapy to more than 3 vertebrae.

         10. Active serious bacterial or fungal infections; &gt;grade 3 National Cancer Institute
             (NCI) Common Terminology Criteria for Adverse Events (CTCAE).

         11. Receipt of haematopoietic cytokines within 10 days of study drug administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hartmut Goldschmidt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine V</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2010</study_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematopoietic stem cells</keyword>
  <keyword>Mobilisation</keyword>
  <keyword>Autologous transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

